[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Jimenez-Pacheco et al., 2017 - Google Patents

Epigenetic mechanisms of gene regulation in amyotrophic lateral sclerosis

Jimenez-Pacheco et al., 2017

View PDF
Document ID
8134300505407668313
Author
Jimenez-Pacheco A
Franco J
Lopez S
Gomez-Zumaquero J
Magdalena Leal-Lasarte M
Caballero-Hernandez D
Cejudo-Guillén M
Pozo D
Publication year
Publication venue
Neuroepigenomics in Aging and Disease

External Links

Snippet

Despite being clinically described 150 years ago, the mechanisms underlying amyotrophic lateral sclerosis (ALS) pathogenesis have not yet been fully understood. Studies in both animal models of ALS and human patients reveal a plethora of alterations such as increased …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Jimenez-Pacheco et al. Epigenetic mechanisms of gene regulation in amyotrophic lateral sclerosis
Wu et al. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Bertogliat et al. Epigenetic mechanisms of neurodegenerative diseases and acute brain injury
Wang et al. Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy
Szyf Prospects for the development of epigenetic drugs for CNS conditions
Lee et al. Modeling ALS and FTD with iPSC-derived neurons
Paez-Colasante et al. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era
Day et al. Epigenetic treatments for cognitive impairments
Niederberger et al. Drugging the pain epigenome
Junn et al. MicroRNAs in neurodegenerative diseases and their therapeutic potential
Rinchetti et al. MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis
Adwan et al. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease
Waseem Bihaqi et al. Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm
Ihezie et al. Epigenetics in blood–brain barrier disruption
Narayan et al. Pharmacology of epigenetics in brain disorders
A Kamal et al. Current update on synopsis of miRNA dysregulation in neurological disorders
D’Mello III MECP2 and the biology of MECP2 duplication syndrome
Goodwin et al. RNA-binding protein misregulation in microsatellite expansion disorders
Bourassa et al. The interplay between microRNAs and histone deacetylases in neurological diseases
Cacabelos et al. Epigenomics of Alzheimer's disease
US20180318285A1 (en) Methods for treatment of autism spectrum disorders
Chen et al. The pathogenesis of amyotrophic lateral sclerosis: Mitochondrial dysfunction, protein misfolding and epigenetics
Navarrete-Modesto et al. The molecular hallmarks of epigenetic effects mediated by antiepileptic drugs
Mir et al. Neuroepigenetics of ageing and neurodegeneration-associated dementia: An updated review
Paniri et al. Alzheimer’s disease-related epigenetic changes: novel therapeutic targets